Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.
Fiche publication
Date publication
janvier 2020
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Pr DECONINCK Eric, Dr FERRAND Christophe, Dr DESCHAMPS Marina, Dr DAGUINDAU Etienne
Tous les auteurs :
Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, Trad R, Deconinck E, Deschamps M, Ferrand C
Lien Pubmed
Résumé
Recent studies have provided several insights into acute myeloid leukemia. Studies based on molecular biology have identified eight functional mutations involved in leukemogenesis, including driver and passenger mutations. Insight into Leukemia stem cells (LSCs) and assessment of cell surface markers have enabled characterization of LSCs from hematopoietic stem and progenitor cells. Clonal evolution has been described as having an effect similar to that of microenvironment alterations. Such biological findings have enabled the development of new targeted drugs, including drug inhibitors and monoclonal antibodies with blockage functions. Some recently approved targeted drugs have resulted in new therapeutic strategies that enhance standard intensive chemotherapy regimens as well as supportive care regimens. Besides the progress made in adoptive immunotherapy, since allogenic hematopoietic stem cell transplantation enabled the development of new T-cell transfer therapies, such as chimeric antigen receptor T-cell and transgenic TCR T-cell engineering, new promising strategies that are investigated.
Mots clés
CAR T cells, acute myeloid leukemia, clinical trials, immunotherapies, management
Référence
Front Oncol. 2020 ;10:599933